Related Experiment Video
Updated: Jun 28, 2025
Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
Published on: August 4, 2022
Evaluation of Alacepril Administration in Canine Patent Ductus Arteriosus According to Plasma Chymase Activity
Kazumi Shimada1, Miki Hirose1, Lina Hamabe1
1Department of Veterinary Medicine, Facility of Agriculture, Tokyo University of Agriculture and Technology, Fuchu 183-8509, Japan.
Insights
Plasma chymase activity increased after administering angiotensin-converting enzyme (ACE) inhibitor alacepril in puppies with patent ductus arteriosus (PDA). This suggests chymase activity may help assess cardiac disease in veterinary medicine.
Area of Science:
- Cardiovascular Physiology
- Veterinary Cardiology
- Pharmacology
Background:
- Chymase, within the renin-angiotensin system (RAS), contributes to cardiac disease progression by producing angiotensin II during tissue injury.
- Plasma chymase activity correlates with hemodynamic changes, offering insights into patent ductus arteriosus (PDA) pathophysiology.
Purpose of the Study:
- To investigate the relationship between plasma chymase activity and the administration of an angiotensin-converting enzyme (ACE) inhibitor in canine PDA.
- To evaluate the effect of alacepril on plasma chymase activity and hemodynamic parameters in puppies with PDA.
Main Methods:
- Thirteen puppies diagnosed with PDA received alacepril treatment.
- Echocardiography and non-invasive blood pressure measurements were conducted before and after alacepril administration.
- Plasma chymase activity was quantified using a colorimetric absorbance method.
Main Results:
- Plasma chymase activity showed a significant increase following alacepril administration.
- A significant decrease in blood pressure was observed concurrently with the rise in chymase activity.
- Alacepril treatment altered and affected plasma chymase activity in PDA cases.
Conclusions:
- ACE inhibition with alacepril leads to increased plasma chymase activity in PDA.
- Plasma chymase activity may serve as a novel biomarker for evaluating cardiac disease pathology and therapeutic response in veterinary medicine.
Abstract:
Chymase in the renin-angiotensin system (RAS) actively contributes to cardiac disease progression. Chymase is activated to produce angiotensin II during tissue injury and is involved in hemodynamics. A recent study demonstrated that plasma chymase activity reflects hemodynamic changes and aids in understanding patent ductus arteriosus (PDA) pathophysiology. The present study examined the relationship between plasma chymase activity and the administration of angiotensin-converting enzyme (ACE) inhibitor. Alacepril was administered to 13 puppies with PDA. Conventional echocardiographic parameters and non-invasive blood pressure were measured before and after medication. Plasma chymase activity was calculated using the colorimetric absorbance method. Plasma chymase activity significantly increased, but blood pressure significantly decreased. We detected an increase in plasma chymase activity due to ACE inhibition in PDA cases treated with alacepril. Plasma chymase activity was affected and altered by alacepril. In veterinary medicine, plasma chymase activity may be a novel method for assessing the pathology of and therapy for cardiac diseases.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors